Get the Stockscreener App
10.63
1.76%
-0.19
After Hours:
10.68
0.05
+0.47%
Celcuity Inc stock is traded at $10.63, with a volume of 115.98K.
It is down -1.76% in the last 24 hours and down -5.26% over the past month.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
See More
Previous Close:
$10.82
Open:
$10.74
24h Volume:
115.98K
Relative Volume:
0.46
Market Cap:
$402.56M
Revenue:
-
Net Income/Loss:
$-63.78M
P/E Ratio:
-3.9664
EPS:
-2.68
Net Cash Flow:
$-53.91M
1W Performance:
+1.82%
1M Performance:
-5.26%
6M Performance:
-16.95%
1Y Performance:
-29.60%
1-Day Range:
$10.50
$10.82
1-Week Range:
$10.26
$10.88
52-Week Range:
$7.575
$19.77
Celcuity Inc Stock (CELC) Company Profile
Name
Celcuity Inc
Sector
Industry
Phone
763-392-0767
Address
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
10.63 | 395.32M | 0 | -63.78M | -53.91M | -2.68 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Feb-22-24 | Initiated | Stifel | Buy |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Oct-08-21 | Initiated | Canaccord Genuity | Buy |
| Sep-07-21 | Initiated | Jefferies | Buy |
| Jul-29-21 | Initiated | Cowen | Outperform |
| Jul-27-21 | Initiated | Needham | Buy |
| Jan-28-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| May-11-20 | Resumed | Craig Hallum | Buy |
| Nov-20-18 | Initiated | H.C. Wainwright | Buy |
View All
Celcuity Inc Stock (CELC) Latest News
Bank of America Corp DE Has $3.77 Million Stock Holdings in Celcuity Inc. (NASDAQ:CELC) - Defense World
Celcuity at TD Cowen’s Oncology Summit: Exploring Gadotelisib’s Potential By Investing.com - Investing.com Canada
Celcuity at TD Cowen’s Oncology Summit: Exploring Gadotelisib’s Potential - Investing.com Australia
Ameriprise Financial Inc. Has $5.85 Million Stock Holdings in Celcuity Inc. (NASDAQ:CELC) - Defense World
Celcuity Inc. (NASDAQ:CELC) Shares Bought by Northern Trust Corp - Defense World
Q1 Earnings Estimate for Celcuity Issued By HC Wainwright - Defense World
HC Wainwright Analysts Lift Earnings Estimates for Celcuity - Defense World
Brokerages Set Celcuity Inc. (NASDAQ:CELC) Target Price at $30.80 - Defense World
Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual Congress - ACCESS Newswire
How To Trade (CELC) - news.stocktradersdaily.com
Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences - GlobeNewswire
Celcuity’s (CELC) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
HC Wainwright & Co. Reiterates Buy Rating on Celcuity (CELC) with $27 Target | CELC Stock News - GuruFocus
The Manufacturers Life Insurance Company Invests $142,000 in Celcuity Inc. (NASDAQ:CELC) - Defense World
Price T Rowe Associates Inc. MD Takes $167,000 Position in Celcuity Inc. (NASDAQ:CELC) - Defense World
Needham & Company LLC Reaffirms “Buy” Rating for Celcuity (NASDAQ:CELC) - Defense World
Celcuity outlines $2B peak revenue potential for gedatolisib as Phase 3 breast cancer trials progress - MSN
Celcuity Approves Stock Plan Amendment at Annual Meeting - TipRanks
Celcuity Inc. (NASDAQ:CELC) Q1 2025 Earnings Call Transcript - Insider Monkey
Celcuity (CELC) Maintains Strong "Buy" Rating from Needham | CEL - GuruFocus
Celcuity Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Celcuity Inc. Reports Q1 2025 Financial Results - TipRanks
Celcuity Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:CELC) - Seeking Alpha
Earnings call transcript: Celcuity Q1 2025 reports wider loss, stable stock - Investing.com
Transcript : Celcuity Inc., Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
Celcuity (CELC) to Release Quarterly Earnings on Wednesday - Defense World
(CELC) Long Term Investment Analysis - news.stocktradersdaily.com
Celcuity Inc. (NASDAQ:CELC) Shares Acquired by Wells Fargo & Company MN - Defense World
MetLife Investment Management LLC Buys 6,669 Shares of Celcuity Inc. (NASDAQ:CELC) - Defense World
Celcuity Inc. to Release First Quarter 2025 Financial Results on May 14, 2025 - Nasdaq
Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call - GlobeNewswire
Barclays PLC Acquires 3,594 Shares of Celcuity Inc. (NASDAQ:CELC) - Defense World
JPMorgan Chase & Co. Has $192,000 Stake in Celcuity Inc. (NASDAQ:CELC) - Defense World
Q1 Earnings Estimate for Celcuity Issued By Leerink Partnrs - Defense World
When (CELC) Moves Investors should Listen - news.stocktradersdaily.com
Brokerages Set Celcuity Inc. (NASDAQ:CELC) Price Target at $30.17 - Defense World
Celcuity Inc. Announces $50 Million Private Placement - ACCESS Newswire
Celcuity Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Updates - ACCESS Newswire
Geode Capital Management LLC Acquires 62,003 Shares of Celcuity Inc. (NASDAQ:CELC) - Defense World
Northrop Grumman Posts Downbeat Results, Joins Halliburton And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Is Celcuity (NASDAQ:CELC) Using Debt Sensibly? - simplywall.st
Celcuity Inc. (NASDAQ:CELC) Stock Holdings Lifted by Vanguard Group Inc. - Defense World
Where are the Opportunities in (CELC) - news.stocktradersdaily.com
Celcuity Inc. (NASDAQ:CELC) Shares Purchased by Wellington Management Group LLP - Defense World
Corebridge Financial Inc. Has $213,000 Position in Celcuity Inc. (NASDAQ:CELC) - Defense World
Needham & Company LLC Reiterates “Buy” Rating for Celcuity (NASDAQ:CELC) - Defense World
Celcuity at Needham Conference: New Frontiers in Cancer Treatment By Investing.com - Investing.com Canada
Celcuity at Stifel Forum: Insights on Cancer Drug Trials By Investing.com - Investing.com Canada
Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Celcuity Inc Stock (CELC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):